Analysts Conflicted on These Healthcare Names: Sucampo Pharmaceuticals (NASDAQ: SCMP), Revance Therapeutics (NASDAQ: RVNC) and Wright Medical Group (NASDAQ: WMGI)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sucampo Pharmaceuticals (NASDAQ: SCMP), Revance Therapeutics (NASDAQ: RVNC) and Wright Medical Group (NASDAQ: WMGI).

Sucampo Pharmaceuticals (NASDAQ: SCMP)

B.Riley FBR analyst David Buck assigned a Buy rating to Sucampo Pharmaceuticals (NASDAQ: SCMP) today and set a price target of $18. The company’s shares closed yesterday at $14.20.

Buck observed:

“For Buy-rated Sucampo (SCMP), we continue to see upside for shares over the next twelve months and we increase our price target from $14 to $18 per share as we focus valuation on 2019. We note that shares have advanced by ~41% since Sucampo’s R&D meeting on November 16th featuring a focus on Sucampo’s late-stage pipeline for rare diseases. In contrast to Sucampo’s move, the S&P Composite 1500 Pharmaceuticals, Biotechology and Life Sciences index (SP603) has gained just 0.5% and the NASDAQ Biotech index (NBI) has gained just 0.8%. Sucampo’s November 16th meeting featured key speakers on late-stage pipeline projects aimed at Niemann-Pick type C-1 (NPC-1) disease (progressive and ultimately fatal disease with neurological and psychiatric progression) and gastro-intestinal disorder FAP (familial adenomatous polyposis).”

According to TipRanks.com, Buck is a 4-star analyst with an average return of 11.8% and a 57.1% success rate. Buck covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Amag Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Sucampo Pharmaceuticals is Strong Buy and the average price target is $21.13, representing a 48.8% upside.

In a report issued on November 21, Maxim Group also assigned a Buy rating to the stock with a $23 price target.
Revance Therapeutics (NASDAQ: RVNC)

In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $54. The company’s shares closed yesterday at $34.75, close to its 52-week high of $37.20.

Yang wrote:

“We came away impressed by the results including multiple secondary endpoints demonstrating RT002’s impressive enhanced duration in addition to hitting primary end point solidly. We gain greater confidence in the approval and market potential of RT002 and raise our PT to $54.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.6% and a 49.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Fennec Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Revance Therapeutics is Strong Buy and the average price target is $39, representing a 12.2% upside.

In a report issued on November 27, Barclays also initiated coverage with a Buy rating on the stock with a $31 price target.
Wright Medical Group (NASDAQ: WMGI)

Needham analyst Michael Matson assigned a Hold rating to Wright Medical Group (NASDAQ: WMGI) today. The company’s shares closed yesterday at $23.17, close to its 52-week low of $22.14.

Matson observed:

“We are adjusting our estimates to better reflect management’s commentary on the 3Q17 call regarding fewer selling days in 2018 and the Salto ankle divestiture. Specifically, we lowered our growth estimates for Lower Extremities and Biologics and raised our growth estimates for Upper Extremities. We also lowered our 2018E revenue estimate to reflect four fewer selling days in 4Q18 (~$7M impact) and the divestiture of the international Salto ankle business (~$4M impact).”

According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.9% and a 55.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

Wright Medical Group has an analyst consensus of Strong Buy, with a price target consensus of $31.14.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.